当前位置: 首页 > 期刊 > 《中国当代医药》 > 2011年第2期 > 正文
编号:12009372
ELISA法检测外周血环氧合酶-2活性在亚临床冠状动脉粥样硬化中的应用探讨(1)
http://www.100md.com 2011年1月15日
第1页

    参见附件(1328KB,2页)。

     [摘要] 目的:探讨酶联免疫法(ELISA)检测外周血环氧合酶-2(COX-2)活性在亚临床冠状动脉粥样硬化(AS)中的应用价值。方法:应用选择性COX-2抑制剂(塞来昔布)对亚临床冠状动脉粥样硬化进行短期干预,ELISA法检测各分组血浆COX-2水平,并结合临床资料进行分析。结果:亚临床AS组COX-2水平[(10.84±3.11)U/L],明显高于正常对照组[(6.97±1.25)U/L](P<0.05);塞来昔布组在接受塞来昔布后COX-2水平显著降低(P<0.05),接近正常对照组水平(P>0.05),与安慰剂组有明显差异(P<0.05)。结论:亚临床AS血浆COX-2水平明显升高,ELISA法测定血浆COX-2活性可作为亚临床AS的诊断、预后的参考指标。

    [关键词] ELISA法,COX-2;选择性COX-2抑制剂;动脉粥样硬化

    [中图分类号] R543.3 [文献标识码]A[文章编号]1674-4721(2011)01(b)-030-02

    The application discussion of ELISA to detect PB COX-2 activity on subclinical coronary atherosclerosis

    LIU Xuhua, ZHU Minghui, GUO Kai

    (The People's Hospital of Zhengzhou City, Henan Province, Zhengzhou450003,China)

    [Abstract] Objective: To discuss the value of ELISA to detect the application of peripheral blood COX-2 activity on subclinical coronary atherosclerosis. Methods: Used selective COX-2 inhibitors (celecoxib) to perform short-term intervention on sub-clinical coronary atherosclerosis anddetected different groups of plasma COX-2 by ELISA and analyzed with clinical data. Results: The level of subclinical coronary AS group was [(10.84±3.11) U/L], which was obviously higher than that of the normal comparison group[(6.97±1.25) U/L]; The difference between celecoxib group and placebo group was significant (P<0.05); and the level of COX-2 obviously reduced after receiving celecoxib, no difference compared with the normal group(P<0.05). Conclusion: COX-2 level is significantly associated with subclinical coronary atherosclerosis(AS), and detecting the activity of plasma COX-2 by ELISA can be used as diagnosis of subclinical coronary atherosclerosis and a reference indicator to prognostic.

    [Key words] ELISA; COX-2; Selective COX-2 inhibitors; Atheroselerosis

    环氧合酶-2通过活化的巨噬细胞调节前列腺素(PGE2)的合成,与炎症和动脉粥样硬化的发生有关。研究发现[1-2]COX-2在AS病变处表达,并受多种炎性细胞因子调节,而其代谢产物也具有促进炎症作用,这表明它参与了AS形成和发展的病理过程,而抑制COX-2作为AS新的治疗手段,虽然尚存争议,但已初步在临床应用。本研究应用ELISA法检测各分组血浆COX-2活性,快速简捷,可作为亚临床AS的诊断、预后诊断的参考指标。现报道如下:

    1 资料与方法

    1.1一般资料

    对象均为2008年1月~2009年10月本院门诊患者和健康体检者。亚临床AS组选取100例[男62例,女38例,年龄27~82岁,平均(54.0±12 ......

您现在查看是摘要介绍页,详见PDF附件(1328KB,2页)